Key Takeaways:
ADMA Biologics (Nasdaq: ADMA) shares plunged more than 24 percent in after-hours trading on May 6 after law firm Block & Leviton announced an investigation into the company for potential securities fraud.
The investigation follows a March report from short-seller Culper Research that alleged ADMA "induced distributors to stock excess ASCENIV by offering rebates and extended payment terms." Culper claimed this practice masked what was actually a 3 percent revenue decline in 2025, contrary to the 20 percent growth ADMA reported.
The stock, which closed the regular session at $10.11, fell to near $7.73 in late trading. The sharp decline came as the plasma-derived biologics company was set to report first-quarter earnings, where analysts had expected earnings per share of $0.195 on revenue of $142.74 million.
The fraud investigation amplifies scrutiny of ADMA's revenue quality, creating a stark conflict for investors between the bearish allegations and bullish analyst models. The company's stock now trades more than 67 percent below its 52-week high of $23.98, set earlier this year.
Wall Street remains sharply divided on ADMA's prospects. Before the investigation was announced, three of four analysts covering the stock rated it a buy, with a consensus price target of $20.67 implying over 100 percent upside from its closing price. Valuation models based on discounted cash flow analysis from Simply Wall St suggested an even greater disconnect, with one estimate placing the company's intrinsic value at $52.93 per share, or 80 percent above its current price.
However, the channel stuffing allegations have given investors pause. Cantor Fitzgerald downgraded the stock to neutral in late March, citing "concerns around increased days sales outstanding and accounts receivables." While Mizuho maintained its buy rating, it slashed its price target from $30 to $24.
The core of the allegations centers on how ADMA recognizes revenue for its primary immunoglobulin product, ASCENIV. Investors will be focused on the company's cash flow from operations and working capital metrics in the upcoming earnings report to gauge the quality of its reported sales. The recent May 4 FDA approval to expand ASCENIV’s label to pediatric patients, once seen as a clear growth catalyst, is now overshadowed by questions of whether demand can absorb existing inventory at distributors.
The sell-off pushes ADMA Biologics shares to their lowest levels since the initial short-seller report, testing investor conviction in the face of serious legal and accounting challenges. The company's official response to the allegations during its earnings call will be a critical catalyst for the stock.
This article is for informational purposes only and does not constitute investment advice.
